德国和法国抗癌药物价格的决定因素：多元回归分析。

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-12 DOI:10.1080/14737167.2025.2518140

Nethra Subramanian, Aadhav Subramanian

{"title":"德国和法国抗癌药物价格的决定因素：多元回归分析。","authors":"Nethra Subramanian, Aadhav Subramanian","doi":"10.1080/14737167.2025.2518140","DOIUrl":null,"url":null,"abstract":"Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France.Research design and methods: Cancer drugs approved in EU between 2011 and 2022 with available benefit assessments and prices were analyzed. Monthly treatment cost was the dependent variable; approval year, orphan status, benefit rating, number of comparators, and target population size were independent variables. Univariate and multiple regression analyses were conducted.Results: The analysis included 107 drugs in Germany and 70 in France. In Germany, univariate analysis showed significance for benefit magnitude, orphan status, number of comparators, target population, and approval year. In France, orphan status, number of comparators, target population, and approval year were significant. Regression models showed that log target population (p < 0.0001), approval year (p = 0.021), and major/considerable benefit (p < 0.0001) were significant in Germany; log target population (p = 0.001) and ASMR II/III (p = 0.017) were significant in France.Conclusions: Target population and benefit rating are drivers of cancer drug prices in Germany and France. The analysis provides quantitative evidence on the association between cancer rarity and price, which could inform policy.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Determinants of cancer drug prices in Germany and France: a multiple regression analysis.\",\"authors\":\"Nethra Subramanian, Aadhav Subramanian\",\"doi\":\"10.1080/14737167.2025.2518140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France.Research design and methods: Cancer drugs approved in EU between 2011 and 2022 with available benefit assessments and prices were analyzed. Monthly treatment cost was the dependent variable; approval year, orphan status, benefit rating, number of comparators, and target population size were independent variables. Univariate and multiple regression analyses were conducted.Results: The analysis included 107 drugs in Germany and 70 in France. In Germany, univariate analysis showed significance for benefit magnitude, orphan status, number of comparators, target population, and approval year. In France, orphan status, number of comparators, target population, and approval year were significant. Regression models showed that log target population (p < 0.0001), approval year (p = 0.021), and major/considerable benefit (p < 0.0001) were significant in Germany; log target population (p = 0.001) and ASMR II/III (p = 0.017) were significant in France.Conclusions: Target population and benefit rating are drivers of cancer drug prices in Germany and France. The analysis provides quantitative evidence on the association between cancer rarity and price, which could inform policy.\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2025.2518140\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2518140","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

背景：针对罕见癌症的药物价格上涨可能是合理的，但其程度仍不确定。本研究分析了德国和法国癌症药物价格的决定因素。研究设计和方法：分析2011年至2022年在欧盟批准的抗癌药物的可用效益评估和价格。每月治疗费用为因变量；批准年份、孤儿状态、获益等级、比较者数量和目标人群规模为自变量。进行单因素和多元回归分析。结果：分析了德国107种药物和法国70种药物。在德国，单变量分析显示获益程度、孤儿状态、比较药数量、目标人群和批准年份具有显著性。在法国，孤儿状态、比较药数量、目标人群和批准年份具有显著性。回归模型显示，对数目标人群（p = 0.021）、主要/相当获益（p = 0.001）和ASMR II/III （p = 0.017）在法国具有显著性。结论：目标人群和受益等级是德国和法国癌症药物价格的驱动因素。该分析为癌症罕见度与价格之间的关系提供了定量证据，可以为政策提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Determinants of cancer drug prices in Germany and France: a multiple regression analysis.

Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France.

Research design and methods: Cancer drugs approved in EU between 2011 and 2022 with available benefit assessments and prices were analyzed. Monthly treatment cost was the dependent variable; approval year, orphan status, benefit rating, number of comparators, and target population size were independent variables. Univariate and multiple regression analyses were conducted.

Results: The analysis included 107 drugs in Germany and 70 in France. In Germany, univariate analysis showed significance for benefit magnitude, orphan status, number of comparators, target population, and approval year. In France, orphan status, number of comparators, target population, and approval year were significant. Regression models showed that log target population (p < 0.0001), approval year (p = 0.021), and major/considerable benefit (p < 0.0001) were significant in Germany; log target population (p = 0.001) and ASMR II/III (p = 0.017) were significant in France.

Conclusions: Target population and benefit rating are drivers of cancer drug prices in Germany and France. The analysis provides quantitative evidence on the association between cancer rarity and price, which could inform policy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.